Regeneron Pharmaceuticals and Sanofi have won expanded FDA approval of their blockbuster anti-inflammatory drug Dupixent for the treatment of chronic obstructive pulmonary disease.
Regeneron Pharmaceuticals and Sanofi have won expanded FDA approval of their blockbuster anti-inflammatory drug Dupixent for the treatment of chronic obstructive pulmonary disease.
